Patents by Inventor Jeffrey P. Whitten

Jeffrey P. Whitten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for increasing endogenous levels of corticotropin-releasing factor
    Patent number: 5959109
    Abstract: Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain. Such ligand inhibitors cause release of CRF from the CRF/CRF-binding protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: September 28, 1999
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Jeffrey P. Whitten, James R. McCarthy, Zhengyu Liu, Charles Q. Huang, Philip E. Erickson, Dominic P. Behan
  • Indole derivatives useful to treat estrogen-related neoplasms and disorders
    Patent number: 5877202
    Abstract: The present invention relates to novel indole derivatives useful in down-regulating estrogen receptor expression. Also included are methods for the treatment of neoplasms or of controlling the growth of a neoplasm in a patient afflicted with a neoplastic disease, especially estrogen-dependent neoplasms such as those associated with breast, ovarian and cervical tissue. Another embodiment of the present invention is a method of prophylactically treating a patient at risk of developing a neoplastic disease state. Also provided is a method for treating autoimmune diseases. Also included are pharmaceutical compositions of the novel indole derivatives.
    Type: Grant
    Filed: January 31, 1996
    Date of Patent: March 2, 1999
    Inventors: Alan J. Bitonti, Ian A. McDonald, Francesco G. Salituro, Jeffrey P. Whitten, Esa T. Jarvi, Paul S. Wright
  • CRF receptor antagonists and methods relating thereto
    Patent number: 5795905
    Abstract: CRF receptor antagonists are disclosed. Such receptor antagonists are thiadiazole-, pyrimidine-, triazine-, and triazole-containing compounds substituted with both a C3-C14 monocyclic or fused, homoaryl or heteroaryl group and a substituted amine group. The CFR receptor antagonists have utility in the treatment of a variety of disorders, including disorders associated with the hypersecretion of CRF.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 18, 1998
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: James R. McCarthy, Yun Feng Xie, Jeffrey P. Whitten, Thomas R. Webb, Chen Chen, John Y. Ramphal
  • Modulators of acetylcholine receptors
    Patent number: 5723477
    Abstract: The present invention provides a class of pyridine compounds which are modulators of acetylcholine receptors, i.e., compounds which displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 3, 1998
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Inhibitors of nitric oxide biosynthesis
    Patent number: 5710324
    Abstract: The present invention is directed to a new class of compound which are useful as inhibitors of the biosynthesis of nitric oxide.
    Type: Grant
    Filed: October 4, 1994
    Date of Patent: January 20, 1998
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Ian A. McDonald, Laurie E. Lambert, Niall S. Doherty
  • Modulators of acetylcholine receptors
    Patent number: 5705512
    Abstract: The present invention provides a class of pyridine compounds which are modulators of acetylcholine receptors, i.e., compounds which displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 6, 1998
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Ian A. Mc Donald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Modulators of acetylcholine receptors
    Patent number: 5703100
    Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 30, 1997
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Methods for the preparation of modulators of acetylcholine receptors
    Patent number: 5677459
    Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 14, 1997
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Ian A. Mc Donald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Modulators of acetylcholine receptors
    Patent number: 5594011
    Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: January 14, 1997
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Polycyclic fused ring modulators of acetylcholine receptors
    Patent number: 5567710
    Abstract: In accordance with the present invention, there is provided a class of polycyclic fused ring compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: October 22, 1996
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Jeffrey P. Whitten, Ian A. McDonald, Jean-Michel Vernier
  • N-trityl protected aspartic acid derivatives for the preparation of phosphonate NMDA antagonists
    Patent number: 5554773
    Abstract: The present invention related to novel (R)-dimethyl N-tritylaspartate and novel (R)-alkyl N-trityl-4-oxo-5-phosphononorvalinate derivatives which are useful in the preparation of the class of beta-ketophosphonate NMDA antagonists.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: September 10, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Duane E. Rudisill
  • NMDA antagonists
    Patent number: 5538958
    Abstract: The present invention is directed to a new class of beta-ketone, beta oxime and beta hydrazine phosphonate NMDA antagonists.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 23, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventor: Jeffrey P. Whitten
  • NMDA antagonists
    Patent number: 5500419
    Abstract: The present invention is directed to a new neuroprotective agent. The agent is R-4-oxo-5-phosphononorvaline. This agent is useful in the treatment of ischemic and hypoxic conditions such as stroke.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: March 19, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron
  • Heterocyclic-NMDA antagonists
    Patent number: 5470844
    Abstract: The present invention is directed to a class of 3-phosphono-pyrrolidine derivatives as described by Formula I and their use as NMDA antagonists.
    Type: Grant
    Filed: November 30, 1993
    Date of Patent: November 28, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: Jeffrey P. Whitten
  • R-4-oxo-5 phosphononorvaline used as NMDA antagonists
    Patent number: 5326756
    Abstract: The present invention is directed to a new class of beta-ketone, beta oxime and beta hydrazine phosphonate NMDA antagonists.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: July 5, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron
  • Inhibitors of nitric oxide biosynthesis
    Patent number: 5318992
    Abstract: The present invention is a method of treating hypotension and shock using select ornithine or N.sup.G -arginine derivatives.
    Type: Grant
    Filed: July 13, 1993
    Date of Patent: June 7, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Ian A. McDonald, Laurie E. Lambert, Niall S. Doherty
  • Heterocyclic-NMDA antagonists
    Patent number: 5194430
    Abstract: The present invention is directed to a class of 3-phosphono-piperidine and pyrrolidine derivatives and their use as NMDA antagonists.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: March 16, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: Jeffrey P. Whitten
  • Thione dopamine beta hydroxylase inhibitors
    Patent number: 5189052
    Abstract: Imidazole-2-thione derivatives useful as antihypertensive agents are described herein. The compounds are obtained by cyclization of an appropriate open-chain compound such as an appropriately substituted thiourea.
    Type: Grant
    Filed: December 20, 1989
    Date of Patent: February 23, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, James R. McCarthy, Jeffrey P. Whitten, Robert J. Broersma, Jr.
  • 2,2'-bi-1H-imidazoles
    Patent number: 5147863
    Abstract: This invention relates to novel derivatives of 2,2'-bi-1H-imidazoles, to the processes and intermediates used in their preparation, to their ability to exert the pharmacologic effects of lowering high blood pressure and of increasing heart contractile force and to their use as chemotherpauetic agents useful in treating cardiac insufficiency and hypertension.
    Type: Grant
    Filed: October 17, 1990
    Date of Patent: September 15, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, Jeffrey P. Whitten, James R. McCarthy
  • NMDA antagonists
    Patent number: 5095009
    Abstract: The present invention is directed to a new class of 4-(oxoalkyl)phosphono, 4(oxime alkyl)phosphono, or 4-(hydrazine alkyl)phosphono, 2-piperazine carboxylic derivatives that are useful as NMDA antagonists
    Type: Grant
    Filed: July 20, 1990
    Date of Patent: March 10, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron